Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder

Data presented as a late breaking abstract at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies

Vanda Pharmaceuticals Inc. (Vanda) (VNDA) presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.  Non-24 is a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (synchronize) their master body clock to the 24-hour day.  Currently there is no approved FDA treatment for Non-24.